Negative Results from Phase 2 Clinical Trial of Laquinimod in Primary Progressive MS
December 1, 2017
A phase 2 clinical trial of oral laquinimod in people with primary progressive MS did not meet its primary endpoint of slowing brain atrophy (shrinkage) after 48 weeks, and did not slow progression of disability. The results were announcement by Active Biotech, a company that has been partnering with Teva Pharmaceuticals Industries in the development of Laquinimod.
“This is disappointing news,” noted Bruce Bebo, PhD, Executive Vice President of Research at the National MS Society. “The treatment landscape is changing with the first therapy for primary progressive MS approved
in 2017, but we still have a long way to go to find solutions for everyone living with MS.”
Additional details will be published and presented at a future medical conference.